These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 27488874)
21. Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status. Marchetti C; Ataseven B; Perrone AM; Cassani C; Fruscio R; Sassu CM; Apostol AI; Harter P; De Iaco P; Camnasio CA; Moubarak M; Giannarelli D; Scambia G; Fagotti A Gynecol Oncol; 2024 Aug; 187():170-177. PubMed ID: 38788514 [TBL] [Abstract][Full Text] [Related]
22. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259 [TBL] [Abstract][Full Text] [Related]
23. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384 [TBL] [Abstract][Full Text] [Related]
24. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer. Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778 [TBL] [Abstract][Full Text] [Related]
25. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer]. Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312 [No Abstract] [Full Text] [Related]
26. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. Zaaijer LH; van Doorn HC; Mourits MJ; van Beurden M; de Hullu JA; Adank MA; van Lonkhuijzen LR; Vasen HF; Slangen BF; Gaarenstroom KN; Zweemer RP; Vencken PM; Seynaeve C; Kriege M Br J Cancer; 2016 Nov; 115(10):1174-1178. PubMed ID: 27755534 [TBL] [Abstract][Full Text] [Related]
29. Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study. Muñoz-Repeto I; García MJ; Kamieniak M; Ramón Y Cajal T; Domingo S; Cazorla A; García Donas J; Hernando Polo S; García Sagredo JM; Hernández E; Lacambra C; Saez R; Robles L; Borrego S; Prat J; Palacios J; Benítez J Histol Histopathol; 2013 Jan; 28(1):133-44. PubMed ID: 23233066 [TBL] [Abstract][Full Text] [Related]
30. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704 [TBL] [Abstract][Full Text] [Related]
31. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701 [TBL] [Abstract][Full Text] [Related]
32. No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients. Shawky Ael-A; El-Hafez AA; El-Tantawy D; Hamdy R Asian Pac J Cancer Prev; 2014; 15(10):4275-9. PubMed ID: 24935384 [TBL] [Abstract][Full Text] [Related]
33. Improved survival in women with BRCA-associated ovarian carcinoma. Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470 [TBL] [Abstract][Full Text] [Related]
34. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer. Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Xu K; Yang S; Zhao Y Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218 [TBL] [Abstract][Full Text] [Related]
36. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991 [TBL] [Abstract][Full Text] [Related]
37. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636 [TBL] [Abstract][Full Text] [Related]
38. Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Sabatier R; Lavit E; Moretta J; Lambaudie E; Noguchi T; Eisinger F; Cherau E; Provansal M; Livon D; Rabayrol L; Popovici C; Charaffe-Jauffret E; Sobol H; Viens P Fam Cancer; 2016 Oct; 15(4):497-506. PubMed ID: 26833043 [TBL] [Abstract][Full Text] [Related]
39. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups. Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973 [TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Liu J; Cristea MC; Frankel P; Neuhausen SL; Steele L; Engelstaedter V; Matulonis U; Sand S; Tung N; Garber JE; Weitzel JN Cancer Genet; 2012; 205(1-2):34-41. PubMed ID: 22429596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]